William C. Hahn

Broad Institute

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index148
i10-index357
Publications1,092
Citations103,065

Grants

50 total · 6 active

NIH #5R01CA285582-02

Investigating CREB5-driven mechanisms of immune therapy resistance

Active
Amount
$610K
Period
2024-12-11 → 2029-12-31
PIs
2
Est. capacity / PI
~3 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #1R01CA285582-01A1

Investigating CREB5-driven mechanisms of immune therapy resistance

Active
Amount
$621K
Period
2024-12-11 → 2029-12-31
PIs
2
Est. capacity / PI
~3 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5U01CA274276-04

Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity

Active
Amount
$1.0M
Period
2022-09-19 → 2027-08-31
PIs
3
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

50 total · 6 active

NIH #5R01CA285582-02

Investigating CREB5-driven mechanisms of immune therapy resistance

Active
Amount
$610K
Period
2024-12-11 → 2029-12-31
PIs
2
Est. capacity / PI
~3 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #1R01CA285582-01A1

Investigating CREB5-driven mechanisms of immune therapy resistance

Active
Amount
$621K
Period
2024-12-11 → 2029-12-31
PIs
2
Est. capacity / PI
~3 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5U01CA274276-04

Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity

Active
Amount
$1.0M
Period
2022-09-19 → 2027-08-31
PIs
3
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA274276-03

Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity

Active
Amount
$985K
Period
2022-09-19 → 2027-08-31
PIs
3
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA274276-02

Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity

Active
Amount
$1.0M
Period
2022-09-19 → 2027-08-31
PIs
3
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #1U01CA274276-01

Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity

Active
Amount
$1.0M
Period
2022-09-19 → 2027-08-31
PIs
3
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA266642-04

Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers

Amount
$657K
Period
2022-05-25 → 2026-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #5R01CA266642-03

Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers

Amount
$624K
Period
2022-05-25 → 2026-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #5R01CA266642-02

Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers

Amount
$651K
Period
2022-05-25 → 2026-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #1R01CA266642-01

Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers

Amount
$683K
Period
2022-05-25 → 2026-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #5P01CA154303-10

Project 2: Identification of combination therapy for KRAS-driven lung cancers.

Amount
$289K
Period
2012-05-11 → 2023-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA176058-09

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Amount
$1.0M
Period
2013-05-01 → 2023-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA203655-05

PROJECT 4: Interrogating PP2A Signaling in Human Cancers

Amount
$326K
Period
2017-08-01 → 2023-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA250549-03

Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models

Amount
$964K
Period
2020-06-15 → 2023-05-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA250549-02

Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models

Amount
$963K
Period
2020-06-15 → 2023-05-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #1U01CA250549-01

Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models

Amount
$1.0M
Period
2020-06-15 → 2023-05-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA224146-03

Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens

Amount
$568K
Period
2017-09-30 → 2022-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #4U01CA224146-02

Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens

Amount
$612K
Period
2017-09-30 → 2022-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA154303-09

Project 2: Identification of combination therapy for KRAS-driven lung cancers.

Amount
$289K
Period
2012-05-11 → 2022-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #2P01CA154303-06

Project 2: Identification of combination therapy for KRAS-driven lung cancers.

Amount
$289K
Period
— → 2022-08-31
PIs
1
Est. capacity / PI
~4 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA176058-08

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Amount
$1.0M
Period
2013-05-01 → 2022-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA203655-04

PROJECT 4: Interrogating PP2A Signaling in Human Cancers

Amount
$326K
Period
2017-08-01 → 2022-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA176058-07

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Amount
$969K
Period
2013-05-01 → 2022-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA176058-06

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Amount
$1.0M
Period
2013-05-01 → 2022-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #2U01CA176058-05

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Amount
$1.0M
Period
2013-05-01 → 2022-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #1R03TR003343-01

Novel genetic dependencies in VRK2 methylated glioblastoma multiforme

Amount
$178K
Period
2020-09-01 → 2021-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #3U01CA199253-04S1

Systematic identification of oncogenic KRAS synthetic lethal interactions

Amount
$500K
Period
2015-09-25 → 2020-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #5U01CA199253-04

Systematic identification of oncogenic KRAS synthetic lethal interactions

Amount
$808K
Period
2015-09-25 → 2020-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #1U01CA224146-01

Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens

Amount
$1.8M
Period
2017-09-30 → 2020-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA199253-03

Systematic identification of oncogenic KRAS synthetic lethal interactions

Amount
$808K
Period
2015-09-25 → 2019-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #5U01CA199253-02

Systematic identification of oncogenic KRAS synthetic lethal interactions

Amount
$808K
Period
2015-09-25 → 2019-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #1U01CA199253-01

Systematic identification of oncogenic KRAS synthetic lethal interactions

Amount
$818K
Period
2015-09-25 → 2019-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #5R01CA130988-10

Regulation and function of IKKe in breast cancer initiation and maintenance

Amount
$371K
Period
2007-12-01 → 2019-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA130988-09

Regulation and function of IKKe in breast cancer initiation and maintenance

Amount
$371K
Period
2009-03-01 → 2019-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA130988-08

Regulation and function of IKKe in breast cancer initiation and maintenance

Amount
$371K
Period
2009-03-01 → 2019-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA130988-07

Regulation and function of IKKe in breast cancer initiation and maintenance

Amount
$371K
Period
2009-03-01 → 2019-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA127003-10

Defining Novel Therapeutic Strategies for KRAS-Mutant CRC

Amount
$283K
Period
2007-08-31 → 2019-05-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #4P01CA154303-05

Identification of TBK1 inhibitors in KRAS-dependent lung cancer

Amount
$398K
Period
— → 2017-08-31
PIs
1
Est. capacity / PI
~6 students

Awarded at DANA-FARBER CANCER INST

NIH #4U01CA176058-04

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Amount
$698K
Period
2013-05-01 → 2017-06-30
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA142536-05

Druggable Genetic Lesions in Pediatric Astrocytoma

Amount
$344K
Period
— → 2017-01-31
PIs
1
Est. capacity / PI
~5 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA127003-08

Defining Novel Therapeutic Strategies for KRAS-Mutant CRC

Amount
$213K
Period
2007-08-31 → 2016-06-30
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5U01CA176058-03

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Amount
$703K
Period
2013-05-01 → 2016-04-30
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA154303-04

Identification of TBK1 inhibitors in KRAS-dependent lung cancer

Amount
$398K
Period
— → 2016-04-30
PIs
1
Est. capacity / PI
~6 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01AG023145-10

Regulation and Function of hTERT in Human Cells

Amount
$345K
Period
2004-08-15 → 2015-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA154303-08

Project 2: Identification of combination therapy for KRAS-driven lung cancers.

Amount
$289K
Period
— → —
PIs
1
Est. capacity / PI
~4 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA203655-03

PROJECT 4: Interrogating PP2A Signaling in Human Cancers

Amount
$317K
Period
— → —
PIs
1
Est. capacity / PI
~5 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA154303-07

Project 2: Identification of combination therapy for KRAS-driven lung cancers.

Amount
$289K
Period
— → —
PIs
1
Est. capacity / PI
~4 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA203655-02

PROJECT 4: Interrogating PP2A Signaling in Human Cancers

Amount
$326K
Period
— → —
PIs
1
Est. capacity / PI
~5 students

Awarded at DANA-FARBER CANCER INST

NIH #1P01CA203655-01A1

PROJECT 4: Interrogating PP2A Signaling in Human Cancers

Amount
$329K
Period
— → —
PIs
1
Est. capacity / PI
~5 students

Awarded at DANA-FARBER CANCER INST

NIH #4P50CA127003-09

Defining Novel Therapeutic Strategies for KRAS-Mutant CRC

Amount
$265K
Period
2007-08-31 → —
PIs
1
Est. capacity / PI
~4 students

Awarded at DANA-FARBER CANCER INST

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 40
Open author page on OpenAlex →